HALO on XNAS, Health Care, Halozyme Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Quarterly revenue rose 39% but shares fell 27% in one month while 12-month profit fell 18%.
BadShort interest 12% of shares, 6.8 days to cover
BadInsiders sold $22.1M in 90 days and bought none
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 27 Jan 2027 (an estimate: a year ago it reported on 28 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $493.0M, net income $247.0M.
31 Dec 2021RevenueNet incomeNet losstallest bar $493.0M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$493.0M
$247.0M
30 Jun 2026
$481.0M
$229.9M
31 Mar 2026
$376.7M
$150.0M
31 Dec 2025
$451.8M
-$141.6M
30 Sep 2025
$354.3M
$175.2M
30 Jun 2025
$325.7M
$165.2M
31 Mar 2025
$264.9M
$118.1M
31 Dec 2024
$298.0M
$137.0M
30 Sep 2024
$290.1M
$137.0M
30 Jun 2024
$231.4M
$93.2M
31 Mar 2024
$195.9M
$76.8M
31 Dec 2023
$230.0M
$85.4M
30 Sep 2023
$216.0M
$81.8M
30 Jun 2023
$221.0M
$74.8M
31 Mar 2023
$162.1M
$39.6M
31 Dec 2022
$181.5M
$57.7M
30 Sep 2022
$209.0M
$61.6M
30 Jun 2022
$152.4M
$22.7M
31 Mar 2022
$117.3M
$60.1M
31 Dec 2021
$102.0M
$66.8M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$1.8B
$1.2B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+45%
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$485.4M
$595.5M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$4.01
$4.75
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
82.3%
84.5%
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
37.4%
59.3%
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
26.9%
47.9%
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$885.9M
$602.4M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$1.1B
$702.0M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$3.3B
$1.5B
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$2.2B
$808.8M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
21.5
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
5.8
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
7.0
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
–
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$22.1M
bought $0, sold $22.1M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+18%
768 13F filers vs 651
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
126.5M shares held by 13F filers (30 Sep 2026) of 114.0M outstanding (31 Oct 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
12%
13.7M shares sold short (30 Oct 2026) of 114.0M outstanding (31 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
6.8
13.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
0%
13.7M shares sold short in the report before, 13.7M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
46%
46% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 61%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
9
Tracked since 21 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 21 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+39%
$493.0M vs $354.3M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
+0.7%
$3.0M vs $3.0M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$100K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
34
34 articles in the last 7 days; its usual week has 4.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
7.6×
34 articles in the last 7 days; its usual week has 4.5.
Unusual now sharp changes in the last 90 days, compared with its own past
New institutional positions 155, 1.5× a year earlier
Price $91.35 on 20 Nov 2026, +32% over 12 months (12-month range $61.63 to $131.18)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $50.6M in the last 12 months (the 12 months before: -$28.2M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).Revenue per quarter. Revenue $493.0M in the latest quarter, +39% on a year earlier.Capital spending per quarter. Capital spending $3.0M in the latest quarter, +0.7% on a year earlier.Institutional holders (13F filers). 768 13F filers reported holding it in the latest 13F quarter, +36% on a year earlier.Lobbying spend. Lobbying spend: $100K published in the last 12 months, -58% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $102.0M, -16% on a year earlier; public on 23 Feb 2022
Quarter ended 31 Mar 2022: $117.3M, +32% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $152.4M, +12% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $209.0M, +80% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $181.5M, +78% on a year earlier; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $162.1M, +38% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $221.0M, +45% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $216.0M, +3.4% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $230.0M, +27% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $195.9M, +21% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $231.4M, +4.7% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $290.1M, +34% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $298.0M, +30% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $264.9M, +35% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $325.7M, +41% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $354.3M, +22% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $451.8M, +52% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $376.7M, +42% on a year earlier; public on 12 May 2026
Quarter ended 30 Jun 2026: $481.0M, +48% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $493.0M, +39% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $158K; public on 23 Feb 2022
Quarter ended 31 Mar 2022: $490K, +81% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $968K, +82% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $1.0M, +103% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $2.3M, +1384% on a year earlier; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $11.4M, +2222% on a year earlier; public on 10 May 2023
Quarter ended 30 Sep 2023: $2.9M, +192% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $2.6M, +11% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $3.5M, -69% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $2.6M; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $1.5M, -48% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $3.1M, +18% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $950K, -73% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $1.6M, -39% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $3.0M, +100% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $1.4M, -53% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $3.7M, +294% on a year earlier; public on 12 May 2026
Quarter ended 30 Jun 2026: $4.2M, +167% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $3.0M, +0.7% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 290; public on 14 Feb 2022
31 Mar 2022 report: 294; public on 16 May 2022
30 Jun 2022 report: 338; public on 15 Aug 2022
30 Sep 2022 report: 326; public on 14 Nov 2022
31 Dec 2022 report: 387; public on 14 Feb 2023
31 Mar 2023 report: 355; public on 15 May 2023
30 Jun 2023 report: 344; public on 14 Aug 2023
30 Sep 2023 report: 358; public on 14 Nov 2023
31 Dec 2023 report: 381; public on 14 Feb 2024
31 Mar 2024 report: 393; public on 15 May 2024
30 Jun 2024 report: 436; public on 14 Aug 2024
30 Sep 2024 report: 474; public on 14 Nov 2024
31 Dec 2024 report: 486; public on 14 Feb 2025
31 Mar 2025 report: 519; public on 15 May 2025
30 Jun 2025 report: 517; public on 14 Aug 2025
30 Sep 2025 report: 566; public on 14 Nov 2025
31 Dec 2025 report: 587; public on 17 Feb 2026
31 Mar 2026 report: 615; public on 15 May 2026
30 Jun 2026 report: 651; public on 14 Aug 2026
30 Sep 2026 report: 768; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jul 2023: $20K published
Quarter from 1 Oct 2023: $60K published
Quarter from 1 Jan 2024: $60K published
Quarter from 1 Apr 2024: $60K published
Quarter from 1 Jul 2024: $60K published
Quarter from 1 Oct 2024: $60K published
Quarter from 1 Jan 2025: $60K published
Quarter from 1 Apr 2025: $60K published
Quarter from 1 Jul 2025: $60K published
Quarter from 1 Oct 2025: $60K published
Quarter from 1 Oct 2026: $100K published
What is unusual now
Made public in the last 90 days: it saw 155 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year.
Many funds opening a new position: saw 155 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year Public on 16 Nov 2026.
9 open postings; careers site tracked since 21 Nov 2026. Most in Legal, policy & compliance 22%, Customer success & support 11%, Finance & accounting 11%, Marketing & communications 11%.
Reported lobbying spend: $100K in Q3 2026, $60K in Q3 2025. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
15 Aug 2026
New
Burrell International Group LLCfor Antares Pharma, Inc.
Testosterone replacement therapy; FY28 Defense Authorization and Appropriations.Budget, Defense
Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/accessHealth issues, Medicare/Medicaid, Science/technology
Two or more unrelated kinds of records unusual within 30 days
19 Nov 2024confirmed
Confirmed across sources Institutional holdings and Filings + Financials
Halozyme Therapeutics(HALO): reported revenue of $290.1M for the quarter ended 30 Sep 2024, 1.3× the same quarter last year, while it saw 78 13F filers open a new position in the quarter ended 30 Sep 2024, 2.1× the same quarter last year. Two unrelated kinds of activity within 14 days.
Financials: Quarterly revenue change, became public on 5 Nov 2024
Institutional holdings: Many funds opening a new position, became public on 14 Nov 2024
The quarter ended 30 Sep 2024 against the 8 quarters before it.
this quarterearliernormal: $212.5MSee the evidence (2 changes)
Financials: Quarterly revenue change became public on 5 Nov 2024
Halozyme Therapeutics reported revenue of $290.1M for the quarter ended 30 Sep 2024, 1.3× the same quarter last year.
This period
$290.1M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$212.5M
Typical spread (median absolute deviation)
$17.1M
How far from its usual level
+3.1
Same quarter last year
$216.0M
History used
5,206 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $212.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Institutional holdings: Many funds opening a new position became public on 14 Nov 2024
Halozyme Therapeutics saw 78 13F filers open a new position in the quarter ended 30 Sep 2024, 2.1× the same quarter last year.
This period
78 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
43
Typical spread (median absolute deviation)
4
How far from its usual level
+5.9
Same quarter last year
37
History used
4,018 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 43
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
16 Aug 2022confirmed
Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume
Halozyme Therapeutics(HALO): saw 70 13F filers open a new position in the quarter ended 30 Jun 2022, 2.7× the same quarter last year; it also had 10.7M shares sold short in the 31 Aug 2022 report, 1.8× the same report last year; and it reported revenue of $209.0M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year. Three unrelated kinds of activity within 105 days.
Short interest and volume: Short interest spike, became public on 27 Jul 2022
Institutional holdings: Many funds opening a new position, became public on 15 Aug 2022
Short interest and volume: Short interest spike, became public on 10 Aug 2022
Short interest and volume: Short interest spike, became public on 13 Sep 2022
Short interest and volume: Short interest spike, became public on 27 Sep 2022
Short interest and volume: Short interest spike, became public on 13 Oct 2022
Financials: Quarterly revenue change, became public on 15 Nov 2022
The quarter ended 30 Jun 2022 against the 8 quarters before it.
this quarterearliernormal: 32See the evidence (7 changes)
Short interest and volume: Short interest spike became public on 27 Jul 2022
Halozyme Therapeutics had 8.9M shares sold short in the 15 Jul 2022 report, 1.4× the same report last year.
This period
8.9M (the 15 Jul 2022 report)
Normal report (median of 24 earlier)
6.4M
Typical spread (median absolute deviation)
417K
How far from its usual level
+3.9
Same report last year
6.4M
History used
1,659 days
the 15 Jul 2022 report24 earlier reportsnormal: 6.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 Aug 2022
Halozyme Therapeutics saw 70 13F filers open a new position in the quarter ended 30 Jun 2022, 2.7× the same quarter last year.
This period
70 (the quarter ended 30 Jun 2022)
Normal quarter (median of 8 earlier)
32
Typical spread (median absolute deviation)
6.5
How far from its usual level
+3.9
Same quarter last year
26
History used
3,195 days
the quarter ended 30 Jun 20228 earlier quartersnormal: 32
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 10 Aug 2022
Halozyme Therapeutics had 9.1M shares sold short in the 29 Jul 2022 report, 1.6× the same report last year.
This period
9.1M (the 29 Jul 2022 report)
Normal report (median of 24 earlier)
6.4M
Typical spread (median absolute deviation)
456K
How far from its usual level
+4.0
Same report last year
5.7M
History used
1,673 days
the 29 Jul 2022 report24 earlier reportsnormal: 6.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Sep 2022
Halozyme Therapeutics had 10.7M shares sold short in the 31 Aug 2022 report, 1.8× the same report last year.
This period
10.7M (the 31 Aug 2022 report)
Normal report (median of 24 earlier)
6.5M
Typical spread (median absolute deviation)
591K
How far from its usual level
+4.8
Same report last year
6.0M
History used
1,706 days
the 31 Aug 2022 report24 earlier reportsnormal: 6.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Sep 2022
Halozyme Therapeutics had 10.9M shares sold short in the 15 Sep 2022 report, 1.9× the same report last year.
This period
10.9M (the 15 Sep 2022 report)
Normal report (median of 24 earlier)
6.7M
Typical spread (median absolute deviation)
697K
How far from its usual level
+4.0
Same report last year
5.7M
History used
1,721 days
the 15 Sep 2022 report24 earlier reportsnormal: 6.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Oct 2022
Halozyme Therapeutics had 12.1M shares sold short in the 30 Sep 2022 report, 2.0× the same report last year.
This period
12.1M (the 30 Sep 2022 report)
Normal report (median of 24 earlier)
7.0M
Typical spread (median absolute deviation)
959K
How far from its usual level
+3.6
Same report last year
6.2M
History used
1,736 days
the 30 Sep 2022 report24 earlier reportsnormal: 7.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 15 Nov 2022
Halozyme Therapeutics reported revenue of $209.0M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year.
This period
$209.0M (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
$116.6M
Typical spread (median absolute deviation)
$17.2M
How far from its usual level
+3.6
Same quarter last year
$115.8M
History used
4,475 days
the quarter ended 30 Sep 20228 earlier quartersnormal: $116.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
2 Mar 2021confirmed
Confirmed across sources Institutional holdings and Filings + Financials
Halozyme Therapeutics(HALO): saw 83 13F filers open a new position in the quarter ended 31 Dec 2020, 1.9× the same quarter last year, while it reported revenue of $121.7M for the quarter ended 31 Dec 2020, 2.3× the same quarter last year. Two unrelated kinds of activity within 14 days.
Institutional holdings: Many funds opening a new position, became public on 16 Feb 2021
Financials: Quarterly revenue change, became public on 2 Mar 2021
The quarter ended 31 Dec 2020 against the 8 quarters before it.
this quarterearliernormal: 27See the evidence (2 changes)
Institutional holdings: Many funds opening a new position became public on 16 Feb 2021
Halozyme Therapeutics saw 83 13F filers open a new position in the quarter ended 31 Dec 2020, 1.9× the same quarter last year.
This period
83 (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
27
Typical spread (median absolute deviation)
6
How far from its usual level
+6.3
Same quarter last year
43
History used
2,649 days
the quarter ended 31 Dec 20208 earlier quartersnormal: 27
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Financials: Quarterly revenue change became public on 2 Mar 2021
Halozyme Therapeutics reported revenue of $121.7M for the quarter ended 31 Dec 2020, 2.3× the same quarter last year.
This period
$121.7M (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
$54.4M
Typical spread (median absolute deviation)
$7.0M
How far from its usual level
+6.5
Same quarter last year
$53.7M
History used
3,837 days
the quarter ended 31 Dec 20208 earlier quartersnormal: $54.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
16 Nov 2026Institutional holdings change
saw 155 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year.
Same quarter last year: 105; its normal quarter is 78.5.
See the evidence
This period
155 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
78.5
Typical spread (median absolute deviation)
7
How far from its usual level
+7.4
Same quarter last year
105
History used
4,748 days
the quarter ended 30 Sep 20268 earlier quartersnormal: 78.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $298.0M for the quarter ended 31 Dec 2024, 1.3× the same quarter last year.
Same quarter last year: $230.0M; its normal quarter is $218.5M.
See the evidence
This period
$298.0M (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$218.5M
Typical spread (median absolute deviation)
$17.7M
How far from its usual level
+3.0
Same quarter last year
$230.0M
History used
5,298 days
the quarter ended 31 Dec 20248 earlier quartersnormal: $218.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $290.1M for the quarter ended 30 Sep 2024, 1.3× the same quarter last year, while it saw 78 13F filers open a new position in the quarter ended 30 Sep 2024, 2.1× the same quarter last year. Two unrelated kinds of activity within 14 days.
See the evidence (2 changes)
Financials: Quarterly revenue change became public on 5 Nov 2024
Halozyme Therapeutics reported revenue of $290.1M for the quarter ended 30 Sep 2024, 1.3× the same quarter last year.
This period
$290.1M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$212.5M
Typical spread (median absolute deviation)
$17.1M
How far from its usual level
+3.1
Same quarter last year
$216.0M
History used
5,206 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $212.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Institutional holdings: Many funds opening a new position became public on 14 Nov 2024
Halozyme Therapeutics saw 78 13F filers open a new position in the quarter ended 30 Sep 2024, 2.1× the same quarter last year.
This period
78 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
43
Typical spread (median absolute deviation)
4
How far from its usual level
+5.9
Same quarter last year
37
History used
4,018 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 43
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
14 Nov 2024Institutional holdings change
saw 78 13F filers open a new position in the quarter ended 30 Sep 2024, 2.1× the same quarter last year.
Same quarter last year: 37; its normal quarter is 43.
See the evidence
This period
78 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
43
Typical spread (median absolute deviation)
4
How far from its usual level
+5.9
Same quarter last year
37
History used
4,018 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 43
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $290.1M for the quarter ended 30 Sep 2024, 1.3× the same quarter last year.
Same quarter last year: $216.0M; its normal quarter is $212.5M.
See the evidence
This period
$290.1M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$212.5M
Typical spread (median absolute deviation)
$17.1M
How far from its usual level
+3.1
Same quarter last year
$216.0M
History used
5,206 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $212.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
saw 72 13F filers open a new position in the quarter ended 30 Jun 2024, 1.7× the same quarter last year.
Same quarter last year: 42; its normal quarter is 43.
See the evidence
This period
72 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
43
Typical spread (median absolute deviation)
4
How far from its usual level
+4.9
Same quarter last year
42
History used
3,926 days
the quarter ended 30 Jun 20248 earlier quartersnormal: 43
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
spent $11.4M on capital projects in the quarter ended 31 Mar 2023, 23× the same quarter last year.
Same quarter last year: $490K; its normal quarter is $514K.
See the evidence
This period
$11.4M (the quarter ended 31 Mar 2023)
Normal quarter (median of 8 earlier)
$514K
Typical spread (median absolute deviation)
$300K
How far from its usual level
+10.9
Same quarter last year
$490K
History used
4,565 days
the quarter ended 31 Mar 20238 earlier quartersnormal: $514K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
reported revenue of $209.0M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year.
Same quarter last year: $115.8M; its normal quarter is $116.6M.
See the evidence
This period
$209.0M (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
$116.6M
Typical spread (median absolute deviation)
$17.2M
How far from its usual level
+3.6
Same quarter last year
$115.8M
History used
4,475 days
the quarter ended 30 Sep 20228 earlier quartersnormal: $116.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 12.1M shares sold short in the 30 Sep 2022 report, 2.0× the same report last year.
Same report last year: 6.2M; its normal report is 7.0M.
See the evidence
This period
12.1M (the 30 Sep 2022 report)
Normal report (median of 24 earlier)
7.0M
Typical spread (median absolute deviation)
959K
How far from its usual level
+3.6
Same report last year
6.2M
History used
1,736 days
the 30 Sep 2022 report24 earlier reportsnormal: 7.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.9M shares sold short in the 15 Sep 2022 report, 1.9× the same report last year.
Same report last year: 5.7M; its normal report is 6.7M.
See the evidence
This period
10.9M (the 15 Sep 2022 report)
Normal report (median of 24 earlier)
6.7M
Typical spread (median absolute deviation)
697K
How far from its usual level
+4.0
Same report last year
5.7M
History used
1,721 days
the 15 Sep 2022 report24 earlier reportsnormal: 6.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.7M shares sold short in the 31 Aug 2022 report, 1.8× the same report last year.
Same report last year: 6.0M; its normal report is 6.5M.
See the evidence
This period
10.7M (the 31 Aug 2022 report)
Normal report (median of 24 earlier)
6.5M
Typical spread (median absolute deviation)
591K
How far from its usual level
+4.8
Same report last year
6.0M
History used
1,706 days
the 31 Aug 2022 report24 earlier reportsnormal: 6.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 70 13F filers open a new position in the quarter ended 30 Jun 2022, 2.7× the same quarter last year; it also had 10.7M shares sold short in the 31 Aug 2022 report, 1.8× the same report last year; and it reported revenue of $209.0M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year. Three unrelated kinds of activity within 105 days.
See the evidence (7 changes)
Short interest and volume: Short interest spike became public on 27 Jul 2022
Halozyme Therapeutics had 8.9M shares sold short in the 15 Jul 2022 report, 1.4× the same report last year.
This period
8.9M (the 15 Jul 2022 report)
Normal report (median of 24 earlier)
6.4M
Typical spread (median absolute deviation)
417K
How far from its usual level
+3.9
Same report last year
6.4M
History used
1,659 days
the 15 Jul 2022 report24 earlier reportsnormal: 6.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 Aug 2022
Halozyme Therapeutics saw 70 13F filers open a new position in the quarter ended 30 Jun 2022, 2.7× the same quarter last year.
This period
70 (the quarter ended 30 Jun 2022)
Normal quarter (median of 8 earlier)
32
Typical spread (median absolute deviation)
6.5
How far from its usual level
+3.9
Same quarter last year
26
History used
3,195 days
the quarter ended 30 Jun 20228 earlier quartersnormal: 32
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 10 Aug 2022
Halozyme Therapeutics had 9.1M shares sold short in the 29 Jul 2022 report, 1.6× the same report last year.
This period
9.1M (the 29 Jul 2022 report)
Normal report (median of 24 earlier)
6.4M
Typical spread (median absolute deviation)
456K
How far from its usual level
+4.0
Same report last year
5.7M
History used
1,673 days
the 29 Jul 2022 report24 earlier reportsnormal: 6.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Sep 2022
Halozyme Therapeutics had 10.7M shares sold short in the 31 Aug 2022 report, 1.8× the same report last year.
This period
10.7M (the 31 Aug 2022 report)
Normal report (median of 24 earlier)
6.5M
Typical spread (median absolute deviation)
591K
How far from its usual level
+4.8
Same report last year
6.0M
History used
1,706 days
the 31 Aug 2022 report24 earlier reportsnormal: 6.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Sep 2022
Halozyme Therapeutics had 10.9M shares sold short in the 15 Sep 2022 report, 1.9× the same report last year.
This period
10.9M (the 15 Sep 2022 report)
Normal report (median of 24 earlier)
6.7M
Typical spread (median absolute deviation)
697K
How far from its usual level
+4.0
Same report last year
5.7M
History used
1,721 days
the 15 Sep 2022 report24 earlier reportsnormal: 6.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Oct 2022
Halozyme Therapeutics had 12.1M shares sold short in the 30 Sep 2022 report, 2.0× the same report last year.
This period
12.1M (the 30 Sep 2022 report)
Normal report (median of 24 earlier)
7.0M
Typical spread (median absolute deviation)
959K
How far from its usual level
+3.6
Same report last year
6.2M
History used
1,736 days
the 30 Sep 2022 report24 earlier reportsnormal: 7.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 15 Nov 2022
Halozyme Therapeutics reported revenue of $209.0M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year.
This period
$209.0M (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
$116.6M
Typical spread (median absolute deviation)
$17.2M
How far from its usual level
+3.6
Same quarter last year
$115.8M
History used
4,475 days
the quarter ended 30 Sep 20228 earlier quartersnormal: $116.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 Aug 2022Institutional holdings change
saw 70 13F filers open a new position in the quarter ended 30 Jun 2022, 2.7× the same quarter last year.
Same quarter last year: 26; its normal quarter is 32.
See the evidence
This period
70 (the quarter ended 30 Jun 2022)
Normal quarter (median of 8 earlier)
32
Typical spread (median absolute deviation)
6.5
How far from its usual level
+3.9
Same quarter last year
26
History used
3,195 days
the quarter ended 30 Jun 20228 earlier quartersnormal: 32
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 9.1M shares sold short in the 29 Jul 2022 report, 1.6× the same report last year.
Same report last year: 5.7M; its normal report is 6.4M.
See the evidence
This period
9.1M (the 29 Jul 2022 report)
Normal report (median of 24 earlier)
6.4M
Typical spread (median absolute deviation)
456K
How far from its usual level
+4.0
Same report last year
5.7M
History used
1,673 days
the 29 Jul 2022 report24 earlier reportsnormal: 6.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.9M shares sold short in the 15 Jul 2022 report, 1.4× the same report last year.
Same report last year: 6.4M; its normal report is 6.4M.
See the evidence
This period
8.9M (the 15 Jul 2022 report)
Normal report (median of 24 earlier)
6.4M
Typical spread (median absolute deviation)
417K
How far from its usual level
+3.9
Same report last year
6.4M
History used
1,659 days
the 15 Jul 2022 report24 earlier reportsnormal: 6.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 73 entries; narrow the window or the kind of data to see older ones.
Not listed: 266 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001159036
Ticker
HALO
Domain
halozyme.com
Employer name
antares pharma, antares pharma inc a subsidiary of halozyme (2 unverified)
Hq location
CA|SAN DIEGO|92130 (1 unverified)
Lobbying client
antares pharma, halozyme therapeutics
Name
Antares Pharma, Inc, Antares Pharma IPL AG, Elektrofi Security Corp, GLOBAL YACHT SERVICES INC and 4 more
Uei
L29GR1FX5L24
Wikidata
Q5643474
DOL H-1B labor condition applications and PERM certifications5 data points20 Jul 2026 to 20 Jul 2026
Federal lobbying disclosures (LDA)6 records, 90 data points31 Dec 2005 to 30 Sep 2026
SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)170 records4 Jan 2016 to 5 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1139 data points31 Dec 2008 to 31 Oct 2026
SEC Form 4 insider transactions132 records, 476 data points29 Jun 2018 to 18 Nov 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026